1. Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. Issue 2 (7th July 2021) Authors: Smoot, Kyle; Chen, Chiayi; Stuchiner, Tamela; Lucas, Lindsay; Grote, Lois; Cohan, Stanley Journal: BMJ neurology open Issue: Volume 3:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. COVID-19 in MS: Initial observations from the Pacific Northwest. Issue 5 (September 2020) Authors: Bowen, James D.; Brink, Justine; Brown, Ted R.; Lucassen, Elisabeth B.; Smoot, Kyle; Wundes, Annette; Repovic, Pavle Journal: Neurology Issue: Volume 7:Issue 5(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. New Mole In A College Football Athlete: 849 May 27 3:55 PM ‐ 4:15 PM. (July 2020) Authors: Roberts, Kathleen; Hosey, Robert; Smoot, Kyle Journal: Medicine and science in sports and exercise Issue: Volume 52(2020)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Point Of Care Detection Of VILIP-1 For On-Field Diagnosis Of Sports-Related Concussion: 2257. (September 2022) Authors: Fitzgerald, Michael A.; Roberts, Kathleen; Conley, Caitlin; Lovell, Mark; Wu, Yueming; Kaiser, Kim; Hosey, Rob; Smoot, Kyle Journal: Medicine and science in sports and exercise Issue: Volume 54(2022)Supplement 2 Page Start: 658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Issue 1 (January 2019) Authors: Cohan, Stanley L; Edwards, Keith; Lucas, Lindsay; Gervasi-Follmar, Tiffany; O'Connor, Judy; Siuta, Jessica; Kamath, Vineetha; Garten, Lore; Chen, Chiayi; Thomas, James; Smoot, Kyle; Kresa-Reahl, Kiren; Spinelli, Kateri J Journal: Multiple sclerosis journal, experimental, translational and clinical Issue: Volume 5:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2020) Authors: Cree, Bruce A C; Cutter, Gary; Wolinsky, Jerry S; Freedman, Mark S; Comi, Giancarlo; Giovannoni, Gavin; Hartung, Hans-Peter; Arnold, Douglas; Kuhle, Jens; Block, Valerie; Munschauer, Frederick E; Sedel, Frédéric; Lublin, Fred D; Reingold, Stephen; Duquette, Pierre; Derfuss, Tobias; Fazekas, Franz... Journal: Lancet neurology Issue: Volume 19:Issue 12(2020) Page Start: 988 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide. Issue 4 (October 2021) Authors: Cohan, Stanley; Gervasi-Follmar, Tiffany; Kamath, Aneesh; Kamath, Vineetha; Chen, Chiayi; Smoot, Kyle; Baraban, Elizabeth; Edwards, Keith Journal: Multiple sclerosis journal, experimental, translational and clinical Issue: Volume 7:Issue 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. (June 2018) Authors: Smoot, Kyle; Spinelli, Kateri J; Stuchiner, Tamela; Lucas, Lindsay; Chen, Chiayi; Grote, Lois; Baraban, Elizabeth; Kresa-Reahl, Kiren; Cohan, Stanley Journal: Multiple sclerosis Issue: Volume 24:Number 7(2018) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗